Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Taiwan · Delayed Price · Currency is TWD

81.90

-4.00 (-4.66%)

At close: Jul 28, 2026

TPEX:7871 Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	50.29	50.29	0.8	25.7
Revenue Growth	4801.27%	6162.39%	-96.88%	-
Gross Profit	49.98	49.98	0.17	23.48
Operating Income	-196.55	-196.55	-216.81	-120.95
Net Income	-1,107	-1,107	-440.32	268.21
Earnings Per Share	-14.02	-14.02	-19.90	3.36
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	863.36	863.36	88.12	30.53
Total Debt	24.94	24.94	1,381	778.35
Net Cash (Debt)	838.43	838.43	-1,293	-747.82
Net Cash Growth	28.67%	-	-	-
Net Cash Per Share	10.63	10.63	-58.42	-9.36

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-131.97	-131.97	-239.7	-105.33
Capital Expenditures	-0.5	-0.5	-9.97	-0.22
Free Cash Flow	-132.48	-132.48	-249.67	-105.55
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	99.40%	99.40%	20.67%	91.38%
Operating Margin	-390.85%	-390.85%	-26999.63%	-470.70%
Pretax Margin	-2170.61%	-2170.61%	-54833.75%	1058.35%
Profit Margin	-2200.37%	-2200.37%	-54833.75%	1043.79%
FCF Margin	-263.44%	-263.44%	-31091.78%	-410.76%